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Abstract
Biological drugs opened up new horizons in the ma-
nagement of inflammatory bowel diseases (IBD). 
This study focuses on access to biological therapy in 
IBD patients across 9 selected Central and Eastern 
European (CEE) countries, namely Bulgaria, the 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, 
Poland, Romania and Slovakia. Literature data on 
the epidemiology and disease burden of IBD in CEE 
countries was systematically reviewed. Moreover, we 
provide an estimation on prevalence of IBD as well 
as biological treatment rates. In all countries with the 
exception of Romania, lower biological treatment rates 
were observed in ulcerative colitis (UC) compared 
to Crohn’s disease despite the higher prevalence of 
UC. Great heterogeneity (up to 96-fold) was found in 
access to biologicals across the CEE countries. Poland, 
Bulgaria, Romania and the Baltic States are lagging 
behind Hungary, Slovakia and the Czech Republic in 
their access to biologicals. Variations of reimbursement 
policy may be one of the factors explaining the differ-
ences to a certain extent in Bulgaria, Latvia, Lithuania, 
and Poland, but association with other possible 
determinants (differences in prevalence and incidence, 
price of biologicals, total expenditure on health, 
geographical access, and cost-effectiveness results) 
was not proven. We assume, nevertheless, that health 
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early onset, fluctuating disease course, unpredictable 
prognosis and lack of a cure, IBD poses a conside­
rable burden on patients. 
Introduction of biological drugs in the treatment 
of IBD has brought a paradigm shift in patient ma­
nagement and treatment goals that promoted 
corticosteroid­free clinical, endoscopic, and biomarker 
remission[3,4]. Infliximab was the first biological 
approved by European Medicines Agency (EMA) for 
treatment of CD in 1999, then 7 years later in UC, 
adalimumab was registered in 2007 in CD and 5 years 
later in UC. Furthermore, golimumab received autho­
risation for the treatment of UC in 2013. Although 
biologicals have been marketed in Western Europe 
for over 15 years now, the access is fairly difficult in 
certain CEE countries. Of note, in 2013, biosimilar 
infliximab has been approved for the same indications 
as the original drug and has now been marketed first 
in the CEE region[5], and may affect the access to 
biologicals worldwide as well as in the CEE countries. 
This study aimed to explore access to biological 
therapy of IBD patients in nine Central and Eastern 
European (CEE) countries, namely Bulgaria, the 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, 
Poland, Romania and Slovakia. Literature data was 
systematically reviewed on the epidemiology and 
disease burden of IBD in these CEE countries. We also 
aimed to explore whether the access to biologicals 
is different in these countries and furthermore, to 
identify possible factors that predispose to regional 
differences.
EpidEmiology
Recent data indicate that the incidence and prevalence 
of IBD are increasing over time and in different geo­
graphical locations[6]. In Europe, the annual incidence 
of CD and UC ranges between 0.3­12.7 and 0.6­24.3 
per 100000 person­years, respectively[6]. European 
prevalence rates vary between 4.9­505 per 100000 
persons for UC and 0.6­322 per 100000 persons 
in CD[6]. The peak ages for CD and UC occurrence 
are 20­30 years and 30­40 years, respectively; and 
paediatric IBD accounts for 7%­20% of all cases[1]. 
To provide an insight into the epidemiology of 
IBD in the CEE countries, we relied on the summary 
introduced by Lakatos et al[7] in 2006, and incor­
porated results of a complementary systematic lite­
rature search for the period between 2006 and June 
30th, 2014. We included publications that dealt with 
the 9 selected CEE countries, and excluded those that 
investigated only paediatric IBD (Table 1). 
Overall 17 studies from 7 CEE countries were 
identified with observation periods varying from 1951 
to 2013. No data was available on the epidemiology of 
IBD from Bulgaria or Latvia. To date, only one multi­
country study has been carried out that involved 5 out 
of the 9 countries of interest[8]. Among CEE countries, 
the highest incidence and prevalence rates were noted 
Rencz F et al . Access to biologicals in IBD
1729 February 14, 2015|Volume 21|Issue 6|WJG|www.wjgnet.com
deterioration linked to IBD might be valued differently 
against other systemic inflammatory conditions in 
distinct countries and which may contribute to the 
immense diversity in the utilization of biological drugs 
for IBD. In conclusion, access to biologicals varies 
widely among CEE countries and this difference cannot 
be explained by epidemiological factors, drug prices or 
total health expenditure. Changes in reimbursement 
policy could contribute to better access to biologicals in 
some countries.
Key words: Inflammatory bowel diseases; Ulcerative 
colitis; Biological therapy; Access; Europe, Central and 
Eastern; Crohn’s disease
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Great heterogeneity ranging up to 96-fold 
difference in access of inflammatory bowel diseases 
(IBD) patients to biologicals can be found across 
Central and Eastern Europe (CEE): Poland, Bulgaria, 
Romania, and the Baltic States have, to date, fallen 
behind Hungary, Slovakia and the Czech Republic. 
The following factors did not explain the considerable 
variations among the CEE countries: differences in 
prevalence and incidence, price of biologicals, total 
expenditure on health, geographical access, clinical 
guidelines, and cost-effectiveness results. We assume 
that health deterioration linked to IBD might be 
valued differently against other systemic inflammatory 
conditions in distinct countries which contributes to the 
great heterogeneity.
Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, 
Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, 
Gulácsi L, Lakatos PL. Biological therapy in inflammatory 
bowel diseases: access in Central and Eastern Europe. World J 
Gastroenterol 2015; 21(6): 1728-1737  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i6/1728.htm  DOI: 
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iNTRodUCTioN
Crohn’s disease (CD) and ulcerative colitis (UC) are 
idiopathic, chronic inflammatory disorders of the 
gastrointestinal tract known as inflammatory bowel 
diseases (IBD). In general, IBD is characterised by 
flare­ups and remissions of varying duration and 
severity, and only a minority of patients experience a 
chronic, continuous disease course[1]. CD may involve 
any part of the digestive tract, but mainly affects the 
distal ileum and the colon, whereas UC usually starts 
in the rectum and extends in a continuous retrograde 
manner through part of, or the entire colon[1,2]. Appro­
ximately 80% of CD patients will require at least one 
intestinal surgery, while 10%­30% of UC patients 
will undergo colectomy during their lifetime[1]. Due to 
in Hungary (incidence CD 8.87/105, UC 11.9/105 and 
prevalence CD 115.3/105, UC 211.1/105), while the 
lowest in Romania (incidence CD 0.5/105, UC 0.97/105 
and prevalence CD 1.51/105, UC 2.42/105)[9­11]. Never­
theless, comparison of these studies is hampered 
by the different study designs, investigation periods, 
length of follow­up, country regions, genetic and 
lifestyle characteristics, and age­groups included. 
CEE was previously seen as a low incidence area. 
Nonetheless, more recent data has confirmed increasing 
incidence and prevalence trends. For instance, latest 
studies highlighted that incidence and prevalence in 
certain CEE countries, e.g., the Czech Republic, Estonia, 
Hungary, and Slovakia emerging to that observed in 
Western and Northern European countries[8,10,12]. 
The estimated number of patients annually diag­
nosed with IBD (aged ≥ 15 years) approached 7500 
(55% UC) within the region. Our findings suggest 
that in 2013, there were approximately 235000 IBD 
patients (aged ≥ 15 years) between these countries 
and the proportion of patients with UC added up to 
65% (Table 2). Of note, these patient numbers are 
extrapolations based on available epidemiology data. 
disEasE bURdEN
IBD is a disabling condition that considerably reduces 
patients’ health­related quality of life and influences 
their professional, social and personal lifestyle[13]. 
Due to the early onset and chronic character of the 
disease, patients have to deal with their disorder 
throughout their lifetime. The overall mortality of IBD 
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Table 1  Incidence and prevalence of Crohn's disease and ulcerative colitis in the total population in 9 selected Central and Eastern 
European countries
Ref. Country, region/city Study period Incidence/105 Prevalence/105
CD UC CD UC
Burisch et al[8], 20141 Czech Republic, Prague 2010 5.50   5.5 - -
South Bohemia 3.80   3.8
Bitter and Hulec[45], 1980 Czech Republic, North Bohemia 1968-1978 -   1.3 -   17.6
Nedbal et al[46], 1967 Czech Republic 1960-1965 -   1.4 -   10.7
Salupere[47], 2001 Estonia, Tartu County 1993-1998 1.40   1.7 - -
Kull et al[48], 1998 Estonia, Tartu County 1973-1992 0.27   1.5 - -
Burisch et al[8], 20141 Estonia, Southern Estonia 2010 5.20   5.2 - -
Nagy et al[49], 2004 Hungary, Borsod-Abaúj-Zemplén County 1962-1992 -   1.4 -   10.4
Lakatos et al[10], 2011 Hungary, Western Hungary 2002-2006 8.87 11.9 115.3 211.1
Lakatos et al[9], 2004 Hungary, Veszprém County I: 1997-2001 2.23     5.89   52.9 142.6
P: 1991-2001
Burisch et al[8], 20141 Hungary, Veszprém County 2010 11.5 10.3 - -
Zvirbliene et al[50], 20032 Lithuania 1995-2001 - -   10.0 30-40
Kiudelis et al[51], 2012 Lithuania, Kaunas 2007-2009 1.21     6.56 - -
Burisch et al[8], 20141 Lithuania, Kaunas 2010 2.40   6.1 - -
Chojecki[52], 1964 Poland, Warsaw 1951-1960 0.66 -   66.0 -
Wiercinska-Drapalo et al[53], 2005 Poland, Bialystok 1990-2003 0.10   1.8 - -
Gheorghe et al[54], 1997 Romania, Bucharest 1990-1997 0.42 - - -
Gheorghe et al[11], 2004 Romania, nationwide I: 2002-2003 0.50     0.97     1.51     2.42
P: 2004
Toader[55], 2008 Romania, North-East region 1988-2007 1.54     0.35 - -
Burisch et al[8], 20141 Romania, Timis 2010 1.70   2.4 - -
Príkazská et al[56], 1996 Slovakia, nationwide 1994 6.75 - - -
Príkazka et al[57], 1998 Slovakia, nationwide 1994 - -     6.75 -
Gregus et al[12], 2014 Slovakia 2013 4.60   6.8 80.5 150.5
1Aged ≥ 15 years; 2Extrapolation by Lakatos et al[7], 2006. I: Incidence; P: Prevalence; CD: Crohn's disease; UC: Ulcerative colitis.
Table 2  Estimated number of newly diagnosed and prevalent 
Crohn's disease and ulcerative colitis patients aged ≥ 15 
years in 9 selected Central and Eastern European countries, 
2013
Number of new patients Total patient number
CD UC Total CD UC Total
Bulgaria   208   290   497   6162   11381   17543
Czech Republic   416   416   833   8768   16192   24960
Estonia     58     58   116   1090     2013     3103
Hungary   975   873 1848   9775   17897   27672
Latvia     57     80   137   1695     3131     4826
Lithuania     61   155   216   2482     4584     7066
Poland 1080 1506 2586 32049   59188   91237
Romania   287   405   692 16526   30520   47046
Slovakia   211   311   522   3687     6893   10580
Total 3353 4094 7447 82235 151798 234033
Data sources: Numbers of new patients were estimated based on incidence 
data by Burisch et al[8], 2014. In case of the Czech Republic mean of 
two available regional incidence data was calculated (4.65/105 both for 
CD and UC), and for Bulgaria and Lithuania mean incidence rate of 8 
CEE countries (Croatia, Czech Republic, Estonia, Hungary, Lithuania, 
Moldova, Romania, and Russia) calculated by Burisch et al[8] was applied 
(CD 3.3/105, UC 4.6/105). Total patient number was estimated using data 
from Gregus et al[12], 2014  for Slovakia (CD 80.5/105, UC 150.5/105) and 
Lakatos et al[10], 2011  for Hungary (CD 115.3/105, UC 211.1/105). For the 
other countries mean prevalence rates of Slovakia and Hungary were 
applied (CD 97.9/105, UC 180.8/105). Population data were obtained from 
Eurostat Statistics Database[34]. CD: Crohn's disease; UC: Ulcerative colitis.
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(EUR 1 = USD 1.344, year 2012)[24].
Recently, Mandel et al[25] conducted a research on 
the indirect costs of IBD among 443 patients in Hun­
gary. Applying the HCA method, average total annual 
per patient productivity loss was €1880, of which €1450 
and €430 incurred due to disability­related productivity 
loss and sick leaves from work, respectively (EUR 1 
= HUF 300, year 2013). Annual per patient costs of 
presenteeism in CD and UC patients were reported 
€2605 and €2410, respectively[25].
aCCEss To biologiCal THERapy
So far, the following three biologicals have been re­
gistered for the treatment of IBD by EMA: adalimumab 
and infliximab for the treatment of CD; adalimumab, 
infliximab, and golimumab for the treatment of UC. 
Numbers of gastroenterology centres entitled to 
administer biological therapy in the CEE countries are 
presented in Table 3. In the 9 selected countries, on 
average 784000 inhabitants are covered by a centre; 
nevertheless, in Romania and Latvia this exceeds the 
2 million inhabitants per centre threshold, whereas 
in Estonia, Slovakia and the Czech Republic fewer 
than 500000 inhabitants are referred to each centre 
on average (Figure 1). We found a strong inverse 
correlation between the number of inhabitants 
covered by a centre and countries’ total expenditure 
on health (r = ­0.83, P = 0.005).
Due to the lack of IBD registries covering the 
entire patient population in the CEE countries, partial 
data on biological exposure are available via multiple 
sources such as health insurance databases, IMS 
sales statistics, ministries of health, national gastro­
enterology societies, and personal communication 
(Table 3). We provide an approximate estimation on 
biological treatment rates estimated from prevalence 
data of Table 2 and number of patients with biological 
therapy in Table 3: Hungary 19.1%, Slovakia 18.7%, 
the Czech Republic 11.3%, Estonia 3.9%, Lithuania 
2.9%, Poland 2.8%, Romania 1.5%, Bulgaria 0.7% 
and Latvia 0.2%, respectively. Rates of UC patients 
treated with biologicals are as follows: Slovakia 
6.4%, Hungary 3.5%, Romania 2.1%, Estonia 1.3%, 
Lithuania 1%, Bulgaria and Latvia 0%­0%, respe­
ctively. Taking into consideration the uncertainty in 
prevalence data, we also calculated the biological 
treatment rates based on the number of inhabitants 
for each country. (This approach disregards the 
differences in prevalence across the 9 countries.) Bio­
logical exposure rates are confirmed by the average 
number of patients treated with biologicals per 105 
inhabitants that shows similar distribution (Figure 2). 
However, these geographical access estimations need 
to be interpreted with caution since only patients 
aged ≥ 15 years were taken into consideration, 
and number of patients on biologicals aged < 15 is 
unknown. 
patients is slightly, but significantly higher than in the 
general population with standardized mortality ratios 
of 1.39 for CD and 1.19 for UC, respectively[14,15].
In Western countries, IBD is associated with an 
excessive economic burden. In 2006, the average 
direct medical costs of CD amounted to €2898­6960/
patient/year in Western Europe[16]. Mean annual 
per patient direct medical costs of UC ranged from 
€8949 to €10395, and total economic burden of 
UC accounted for €12.5­29.1 billion annually in 
Europe (2008 prices)[17]. Earlier studies from the past 
decade pointed out that primary cost drivers of IBD 
were surgical treatments and hospitalizations[18,19]. 
Nevertheless, recent studies indicated that healthcare 
costs of IBD have shifted from hospitalization and 
surgery towards drug therapy, mainly due to the 
increasing use of biological drugs[20,21]. Besides medical 
costs, a substantial proportion of patients are young 
adults and thus, indirect costs related to productivity 
loss at work account for about 16%­69% of the total 
burden[17,19­21].
Limited data are available on the costs of IBD 
from the CEE countries[22­25]. In a recently published 
paper within the framework of the Epidemiological 
Committee of European Crohn’s and Colitis Orga­
nisation (ECCO­EpICom), costs for the first year 
of follow­up of newly diagnosed patients, including 
diagnostics and treatment, were estimated[22]. In 
the CEE region (Croatia, the Czech Republic, Estonia, 
Hungary, Lithuania, Moldova, Romania, and Russia) 
annual per patient costs of CD comprised of the 
following items: diagnostics €1264, surgery €19586, 
standard treatment €324, and biologicals €9607, 
respectively, whereas those for UC were: diagnostics 
€740, surgery €14014, standard treatment €513, 
and biologicals €1729, respectively. Cost calculation 
was based on the Danish diagnosis­related group 
(DRG) financing system and costs of medications 
were encountered in Danish prices for all countries; 
thus, results should be interpreted with caution in the 
CEE[22]. 
Direct healthcare costs attributable to IBD were 
investigated in Poland by Meder et al[23]. Between 
2004 and 2007 medical costs of an acute exacerbation 
and a 12­mo follow­up period were calculated in 
41 IBD patients, of whom 7 received surgical and 3 
biological therapy. The average annual per patient 
costs of treatment amounted to €2968 in CD and 
€2540 in UC (EUR 1 = PLN 4.142). The bulk of direct 
costs were related to biological therapy and surgical 
treatment with mean annual per patient costs of €1565 
and €692, respectively[23]. 
In a multicentre study from Poland, indirect costs 
in 256 CD patients (aged 18­65 years, biological 
treatment rate not reported) were determined by 
a human capital approach (HCA)[24]. Per patient 
mean annual costs attributable to absenteeism and 
presenteeism were €2348 and €3011, respectively 
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Price and reimbursement
To focus on prices of biologicals, some differences can 
be noted within the CEE region: adalimumab €957­
€1262, infliximab €481­€617, and golimumab €1067­
€1646 (per dose national list prices)[5]. 
In most CEE countries, biologicals are covered 
at 100% by the health insurance system, although 
share of coverage between pharmaceutical companies 
and insurance funds occurs in certain countries. For 
instance, in Bulgaria 25% is paid by the pharma­
ceutical companies and 75% by the National Health 
Insurance Fund. Among the Baltic States, biological 
therapy is compensated by 100% in Lithuania 
and Estonia, but only 50% of medication cost is 
reimbursed in Latvia, where the other half is financed 
by patient co­payment. All three biologicals approved 
by EMA in IBD indication are reimbursed in CEE except 
for Bulgaria, where original infliximab and golimumab 
do not have reimbursement coverage.
From 2014, biosimilar infliximab began to be mar­
keted in the CEE countries resulting in a price reduction 
of approximately 20%­25%. In Hungary, since May 15, 
newly initiated biological therapy with infliximab must 
be undertaken with a biosimilar antibody. A mandatory 
switch is not recommended; however, relapsers should 
only be treated with a biosimilar if more than a year 
has passed since the termination of the previous 
biological therapy. A somewhat different regulation 
is applied in Poland, where new patients have to be 
treated with a biosimilar, and even patients receiving 
the original drug are forced to switch to biosimilar 
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Table 3  Number of Crohn's disease and ulcerative colitis patients treated with biologicals and centres where biologicals are 
administered in 9 selected Central and Eastern European countries, 2014
Country Number of patients Centres
CD1 UC1 Total
Infliximab Adalimumab Total Infliximab Adalimumab Golimumab Total 
Bulgaria NR     46     46 NR 0 NR       0     46     4
Czech Republic   750   240   990   412 NA NA   412 1402   26
Estonia     29     13     42     21     5   1     27   69     4
Hungary   970   900 1870   460 170   0   630 2500   16
Latvia       1       2       3       0     0   0       0       3     1
Lithuania     30     43     73     15   31   0     46   119     4
Poland   506   382   888 NA NA NA NA   888    502
Romania   114   139   253     73 540 37   650   903     7
Slovakia   350   340   690   320 110 10   440 1130     133
Total 2750 2105 4855 1301 856 48 2205 7060 125
1Including paediatric and adult patients; 2Approximately; 310 adult and 3 paediatric. National gastroenterology societies, ministries of health, IMS data, 
personal communication. NA: Not available; NR: Not reimbursed; CD: Crohn's disease; UC: Ulcerative colitis.
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Figure 1  Number of inhabitants covered by one gastroenterology centre 
entitled to administer biological therapy in 9 selected Central and Eastern 
European countries, 2014. Population data: Eurostat Statistics Database 
(2013)[34], total health expenditure per capita (2012): World Bank Databank[26]. 
BGR: Bulgaria; CZE: Czech Republic; EST: Estonia; HUN: Hungary; LVA: 
Latvia; LTU: Lithuania; POL: Poland; ROM: Romania; SVK: Slovakia.
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Figure 2  Average number of Crohn's disease patients treated with 
biologicals per 105 inhabitants compared to countries per capita total 
expenditure on health. Ulcerative colitis would display a similar figure. Sizes 
of bubbles refer to the absolute number of patients treated with biologicals 
in each country. Data sources: patient numbers: IMS data (2014 or latest 
available), population data: Eurostat Statistics Database (2013)[34], total health 
expenditure per capita (2012): World Bank Databank[26]. BGR: Bulgaria; CZE: 
Czech Republic; EST: Estonia; HUN: Hungary; LVA: Latvia; LTU: Lithuania; 
POL: Poland; ROM: Romania; SVK: Slovakia.
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infliximab as maintenance therapy. By contrast, in 
Romania, switch is not mandated, although in order to 
ensure a price level comparable to the biosimilars for 
patients, surplus costs generated by the prohibition of 
substitution are paid by pharmaceutical companies. 
In Lithuania, from August 1, biosimilar infliximab has 
to be the first­choice for all newly initiated biological 
therapies; however, the original antibodies are financed 
for patients on maintenance therapy with infliximab or 
adalimumab, and a switch is not allowed. The situation 
is unique in Bulgaria, where infliximab has not been 
reimbursed to date, and, hence, IBD patients skipping 
the original infliximab commence their first biological 
therapy with a biosimilar. On the other hand, in the 
Czech Republic either the originally released anti­TNF 
agents or the biosimilars can be used according to 
a physician’s decision, and moreover, after the intro­
duction of the biosimilars, prices of both the originally 
released and the biosimilar drug are required by law to 
be reduced by at least 15%. 
Total per capita expenditure on health in the 9 CEE 
countries varied between $420 (Romania) and $1432 
(Czech Republic) (year 2012)[26]. We observed no 
significant correlation between the average number 
of patients treated with biologicals per 105 inhabitants 
and total health expenditure (Figure 2). Despite 
Hungary, Poland, Lithuania, and Latvia having similar 
total expenditure on health, a higher proportion 
of patients per 105 inhabitants was treated with 
biologicals in Hungary than in the other three countries. 
Furthermore, in Slovakia and the Czech Republic 
a lower proportion of patients per 105 inhabitants 
received biologicals compared to their relatively high 
total health expenditure.
Eligibility criteria
Based on the current diagnostic and treatment 
recommendations of ECCO[27,28], national gastroen­
terology societies have established their own gui­
delines. Several variations can be found across the 
CEE countries regarding the clinical criteria defined 
for eligibility to be treated with biologicals and 
in financing restrictions; we try to point out some 
notable differences between those countries, where 
criteria are clearly stated. 
In most countries, moderate to severe luminal 
CD (Crohn’s Disease Activity Index ­ CDAI > 300 in 
adults), or perianal or fistulising CD, or moderate 
to severe UC patients with immunosuppressant or 
corticosteroid refractory disease, or those with intole­
rance or contraindication to conventional therapies 
are eligible to be treated with biologicals. Efficacy of 
the induction therapy should be evaluated between 
weeks 12 and 16, and maintenance therapy is 
reimbursed for those who fulfil the response criteria 
(luminal CD: ≥ 70 points decrease in CDAI; fistulising 
CD: ≥ 50% reduction in the amount of drainage; UC: 
≥ 50% reduction in UCDAI; corticosteroid­resistant 
UC: 3 points reduction in Mayo score; corticosteroid­
dependent UC: corticosteroid­free remission). 
In Bulgaria and Poland, CD patients’ maintenance 
therapy is reimbursed only up to 12 mo; however, 
in Poland re­treatment is covered after 16 wk after 
the termination of the previous treatment. Criteria 
are more strict for UC, mainly severe patients are 
eligible to receive biological therapy, and additionally, 
treatment duration is also limited, for example, in 
Poland only three doses of infliximab without any 
further continuing treatment can be offered; and in 
Hungary, where UC patients’ maintenance therapy is 
limited to 12 mo; nevertheless, during later flare­ups, 
retreatment is allowed.
Besides, different authorisation processes fun­
ction that can affect the access in CEE. In general, 
gastroenterologists have to request for the biological 
drug from the health insurance company at the 
initiation of the therapy, and additionally they are 
obliged to report on therapeutic outcomes. During 
maintenance treatment, prolongation has to be 
claimed every 6 mo. 
disCUssioN
The objective of this paper is to review the access 
to biological therapy in IBD across 9 selected CEE 
countries. The proportion of patients treated with 
biologicals and average number of patients treated 
per 105 inhabitants were estimated. Potential bias 
due to the unknown validity of country specific IBD 
epidemiology was filtered out using this population­
based calculation. 
In CEE, the estimated proportion of patients 
treated with biologicals vary from 0.2%­19.1% for 
CD and from 0%­6.4% for UC. In the United States, 
a recently published, retrospective analysis of a large 
database containing pharmacy and medical claims 
data of almost 1 million IBD patients indicates that 
16.8% of CD and 3.5% of UC patients were treated 
with biologicals (infliximab, adalimumab, certolizumab 
pegol, natalizumab) between 2010 and 2012[29]. 
This is similar to the treatment patterns of the best­
performing countries from the CEE region. 
In England, it is estimated that in CD and UC, 
13% and 15% of the clinically eligible patients 
received biologicals in 2012[30]. Thus, on average 26 
CD patients were treated with biologicals (infliximab, 
adalimumab) per 105 adults aged ≥ 18 years which 
is higher than the rates observed in any of the CEE 
countries (Figure 2)[30].
In all countries other than Romania, the lower 
biological treatment rates were observed in UC 
compared to CD despite the higher prevalence of UC. 
A possible explanation for the difference is that the 
first biological in UC indication was approved in 2007 
(8 years after CD); therefore, due to the economic 
crisis and the subsequently implemented austerity 
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policies affecting health care spending as well, UC 
patients in these 9 CEE countries were disadvantaged 
compared to patients with either CD or with other 
systemic inflammatory conditions, where biological 
drugs had been used historically. Also, there are 
additional, non­economic determinants promoting 
treatment differences between CD and UC, e.g., 
higher percentage of UC patients had their disease 
controlled with “conventional” therapies and the 
curative surgical option in medical failure[31].
We tried to identify the most important factors 
that are underlying the differences in biological uptake 
among the CEE countries. Experts usually state that 
the following factors might influence the access to 
biologicals: differences in incidence and prevalence, 
price of biologicals, per capita total health expenditure, 
geographical access, clinical and financing guidelines, 
disease burden, cost­effectiveness results of bio­
logicals, medical professionals’ lobbying power, local 
reimbursement policy, and health care financing 
mechanisms. 
In CEE, access to biologicals is highly diverse, 
in certain countries such as Hungary, Slovakia, and 
the Czech Republic, higher number of patients per 
105 inhabitants are treated with biologicals, whereas 
in the Baltic States, Poland, Romania, and Bulgaria 
access to biologicals is rather limited. In addition 
to IBD, heterogeneous access to biologicals was 
reported from 6 CEE countries (Bulgaria, the Czech 
Republic, Hungary, Poland, Romania, and Slovakia) 
in other inflammatory conditions such as rheumatic 
diseases[32]. Nevertheless, access rates in IBD vary 
more extensively across these six CEE countries. Com­
pared to approximately an 8­fold difference noted 
in rheumatoid arthritis (Poland: 1.3% and Slovakia: 
10%)[32], we found up to 27­fold difference in CD 
(Bulgaria: 0.7%, Hungary: 19.1%). In addition, when 
considering all the 9 countries, that difference was as 
high as 96­fold. 
Unfortunately, there are a lack of registries on IBD 
patients on biologicals, and up­to­date epidemiology 
are missing from some countries (Table 1). We pre­
sume, however, that variance in the incidence and 
prevalence of IBD des not explain such great differ­
ences in the access to biological therapy among these 
9 countries. It should be addressed that establishing 
registries would allow not only follow up of patients, 
and provide valid and reliable data about access rates, 
but also might favourably enhance financing and 
reimbursement decision making concerning biologicals 
and additionally biosimilars. 
The difference in the prices of infliximab, ada­
limumab, and golimumab in CEE[33] does not explain 
the extent of heterogeneity for their access. Regarding 
the economic performance, the per capita gross 
domestic product (GDP) as a percentage of EU­27 
countries’ ranges from 52.8% (Bulgaria) to 79.6% (the 
Czech Republic) resulting also a significant differences 
in total expenditure on health[34]. As an example, the 
Czech Republic spends 70% more on health compared 
to Romania and this might contribute to its 8­fold 
higher access rate. However, comparison of Hungary 
and Poland which have very similar total health 
expenditure refutes this assumption since in Poland 
the exposure to biologicals is approximately 10­fold 
lower compared to Hungary (Figure 2). 
The number and geographic distribution of ga­
stroenterology centres offering biological therapy 
can also affect the access in some countries. Ne­
vertheless, Figures 1 and 2 indicate, that contrary 
to a comparable number of patients covered by a 
gastroenterology centre, Poland and Lithuania lag 
behind Hungary in terms of biological treatment rates. 
Various reimbursement coverage of biologicals is 
possibly responsible for the diverse access rates in 
CEE. In all countries but Latvia (50% co­payment), 
biologicals are fully covered and do not require a co­
payment. However, in Romania and Bulgaria, insu­
rance funds and pharmaceuticals share the financing 
in a defined proportion. All countries apply eligibility 
criteria based on the ECCO guidelines as a standard 
for reimbursement, yet there can be marked vari­
ations among the countries in terms of severity 
of disease required and duration of reimbursed 
maintenance therapy. For example, in Bulgaria and 
Poland, the duration of maintenance treatment in CD 
and in Hungary for UC are limited to 12 mo. These 
obstacles likely contribute to the low access rates 
found in Poland and Bulgaria but not in Hungary, 
where despite the 12­mo stopping rule in UC, the 
highest number of UC patients per 105 are treated 
with biologicals among the CEE countries. 
Access to medications is largely determined by 
healthcare financing mechanisms. Most of the 9 coun­
tries share a similar policy and biologicals are covered 
under itemized financing; therefore, differences in 
biological uptake are not explainable by this factor. 
Additionally, in Hungary, a financing guideline on 
biological drugs draws up patient eligibility criteria. 
There is a unique situation in Lithuania, where a quota 
system was established based on the number of 
patients registered by treating centre, and only one in 
every four clinical centres could gain quotas to initiate 
new biological treatments. Thus, from August 1, 2014, 
a total of 23 new IBD patients will receive biological 
therapy within the next 12 mo in the whole country. 
Most CEE countries have implemented a similar 
health technology assessment (HTA) based decision­
making for reimbursement[35]. It is unlikely that 
IBD is unfavourably distinguished in countries with 
established HTA, where reimbursement decisions 
require cost­effectiveness data[35]. Neither variations 
of the estimated utility gain achievable until remission 
as a result of biological therapy (CD: 0.06­0.43, UC: 
0.25­0.47) nor cost­effectiveness of biologicals can 
explain this access gap found between CD and UC in 
CEE[36­39]. Utilities gained as a result of a therapy are 
used to generate quality­adjusted life years (QALYs). 
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QALY is a widely used outcome measure in cost­
effectiveness analysis that takes into account both the 
length and the quality of life spent in a health state[40]. 
A single abstract can be found concerning cost­
effectiveness of biologicals from the CEE countries. 
In Poland, Goszczynska et al[41] conducted a study 
on cost­effectiveness of infliximab as an induction 
therapy in severe active UC. In a 12­mo timeframe 
an incremental cost­utility ratio for infliximab was 
estimated at €16896/QALY compared to colectomy 
that is below the official financing threshold (€24326/
QALY) (EUR 1 = PLN 4.142)[41]. Recently, Gulácsi 
et al[33] have estimated the cost­effectiveness of 
biologicals used in gastroenterology, rheumatology, 
and dermatology. According to the estimates, in the 
Czech Republic, Hungary, Poland, and Slovakia, cost­
effectiveness results are below the threshold of 3 
times per capita GDP/QALY applied in reimbursement 
decision making in many CEE countries. However, 
in Bulgaria and Romania under certain conditions 
this ratio exceeds the threshold[33]. Hence, variations 
of cost­effectiveness ratios in six out of the 9 CEE 
countries do not justify the heterogeneity; for 
example, despite the calculated cost­effectiveness 
data in Poland, exposure to these drugs is rather low. 
Finally, in the field of rheumatology many more 
patients are treated with biologicals than in IBD 
across the CEE countries[32]. However, the prevalence 
of rheumatoid arthritis (RA) remains higher than 
that of IBD with a prevalence of 610/105 inhabitants 
reported in the Czech Republic and a 0.5% prevalence 
in Hungary[42,43]. In addition, comparison of utility gain 
achievable until remission as a result of biological 
therapy is estimated to be similar to CD (0.06­0.43), 
UC (0.25­0.47), and RA (0.15­0.40)[36­39,44]. Inter­
preting these health gain findings requires caution. 
Possible methodological differences must be con­
sidered such as applied outcome measures, patients’ 
baseline quality of life, time frames, and study design. 
Therefore, health gain differences cannot explain 
inequalities in access rates between IBD and RA. 
CoNClUsioN
Access to biologicals varies greatly (up to 96­fold) 
in the selected CEE countries that raises inequity 
concerns regarding access to treatment. To date, 
biological use in IBD in Poland, Bulgaria, Romania, and 
the Baltic States is much lower compared to Hungary, 
Slovakia and Czech Republic. The reason for this 
heterogeneity in the access to biologicals among the 
CEE countries has not been clarified. Differences in 
prevalence and incidence of IBD, prices of biologicals, 
total expenditure on health, geographical access, 
and cost­effectiveness results does not explain the 
above variation. Variations of reimbursement policy 
might explain the differences to a certain extent in 
Bulgaria, Latvia, Lithuania, and Poland. It may be 
also hypothesized that health disability linked to IBD 
might be valued differently against other systemic 
inflammatory conditions in distinct countries. Further 
research, however, is needed to better understand 
the key factors contributing to the above differences 
and investigating future trends.
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